Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate a rapid restart approach of antiretroviral therapy ART for people living with HIV who have stopped treatment for at least 12 weeks. Many individuals face challenges such as side effects, stigma, or difficulty accessing care, which can cause interruptions in their HIV treatment. The study focuses on whether starting treatment quickly with BFTAF, a once-daily oral HIV medication, is safe and effective in helping participants regain control of their HIV and stay engaged in care. Participants will receive the study drug BFTAF, which combines bictegravir, emtricitabine, and tenofovir alafenamide, taken once daily. Those with a higher viral load at the start will take the medication for 48 weeks, while those with suppressed viral load will take it for 24 weeks. The treatment begins on the same day participants return to care, without waiting for baseline lab results, enabling a rapid restart. The study includes two groups viremic participants with HIV-1 RNA 50 copiesmL and virologically suppressed participants with HIV-1 RNA <50 copiesmL. During the study, participants will be monitored through regular assessments for up to 48 weeks depending on their group. Researchers will measure viral load suppression, treatment safety, adherence, resistance, and patient experiences. A subset of participants will also take part in interviews to better understand reasons for stopping and restarting treatment. The study aims to provide insights that could improve support for people living with HIV facing treatment interruptions.